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Abstract
Background: This study aimed to evaluate the clinical outcomes of concurrent liver resection with cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer patients with synchronous liver and
peritoneal metastases.
Methods: Patients with colorectal liver and peritoneal metastasis who underwent complete cytoreduction and
hyperthermic intraperitoneal chemotherapy with concurrent liver surgery between September 2014 and July 2018
were included. Perioperative outcomes, overall survival, and progression-free survival were analyzed retrospectively.
Results: In total, 22 patients were included. The median peritoneal cancer index was 13 (range, 0–26), and the
median number of liver metastases was 3 (range, 1–13). The mean total operative time was 11.4 ± 2.6 h. Minor
postoperative complications (Clavien-Dindo grade I–II) were reported in 10 patients (45.5%), and major
postoperative complications (grade III–V) were reported in five patients (22.7%), including one mortality patient. The
median overall survival since diagnosis with metastasis was 27.4 months. The median overall survival since surgical
intervention and the progression-free survival were 16.7 months and 7.1 months, respectively.
Conclusions: This short-term follow-up study showed that, in an experienced center, combined resection with
hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases was feasible and safe with
acceptable oncologic outcomes.
Keywords: Colorectal cancer, Peritoneal metastases, Liver metastases, Cytoreductive surgery, Hyperthermic
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Background
Approximately 20–25% of colorectal cancer (CRC) patients
are diagnosed with metastatic CR C[1]. The most common
site of metastatic CRC is the liver, accounting for 30–40%
of metastatic CRC cases, and the most common cause of
death is liver metastasis followed by peritoneal metastasis
[2, 3]. Complete resection with systemic chemotherapy is a
potentially curative treatment option for patients with
metastatic CRC. Complete liver resection of hepatic metas-
tasis resulted in a median overall survival (OS) of 30–50
months, and 5-year survival of up to 50% [4]. The develop-
ment of surgical techniques, such as two-stage hepatectomy
and portal vein embolization, can increase the resectability
rate even in patients with multiple, initially unresectable,
liver metastases [5, 6]. For peritoneal metastasis, hyperther-
mic intraperitoneal chemotherapy (HIPEC) after cytoreduc-
tive surgery (CRS) is effective for patients who can achieve
complete cytoreduction. Previous studies, including a ran-
domized trial, showed better survival outcomes and accept-
able morbidity rates in highly selected patients who were
treated with CRS and HIPEC [2, 7–10]. Although recently
PRODIGE-7 trial suggested that the addition of HIPEC
with oxaliplatin does not influence the survival results, it
did not evaluate HIPEC using mitomycin, and the survival
benefit with HIPEC was found in a subgroup with medium
extent of peritoneal carcinomatosis.
However, the inclusion criterion for resection of meta-
static CRC is usually that the metastatic lesion is confined
to a single organ or structure. Combined metastatic CRC
patients are generally recommended palliative systemic
chemotherapy. Patients with combined metastatic sites,
especially those including peritoneal metastasis, have
shorter OS [11]. When systemic chemotherapy was the
only administered treatment, the median OS of patients
with peritoneal metastasis combined with other sites of
metastasis was 12.6months, whereas the median OS of
patients with solitary peritoneal metastasis was 16.3
months [12]. The incidence of synchronous peritoneal
and liver metastases is estimated to be 8% of metastatic
CRC cases, with OS of only 2.6 months when patients do
not receive chemotherapy and OS of 12.0months when
patients receive chemotherapy [13]. Therefore, due to this
poor prognosis, several physicians have attempted surgical
treatment for patients with combined peritoneal and hep-
atic metastases, despite the development of chemothera-
peutic agents. In this study, we aimed to evaluate the
clinical outcomes of CRS and HIPEC with concurrent
liver surgery for patients with synchronous liver and peri-
toneal metastatic CRC.
Methods
Patient selection
From September 2014 to July 2018, patients who under-
went CRS and HIPEC with concurrent liver surgery at
Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul, Republic of Korea were retrospectively
reviewed. We included patients diagnosed with synchron-
ous liver and peritoneal metastases, Eastern Cooperative
Oncologic Group performance status score of < 2, and age
< 80 years. We excluded patients who diagnosed with non-
colorectal origin cancer, other extrahepatic hematogenous
metastasis, and incomplete cytoreduction, indicated by a
completeness of cytoreduction (CC) score of 2 or 3. Con-
current liver surgery included any type of liver resection,
two-stage hepatectomy, and intraoperative radiofrequency
ablation. All patients were preoperatively diagnosed with
metastatic CRC by abdomino-pelvic computed tomography
(CT), liver magnetic resonance imaging, or positron emis-
sion tomography. A multidisciplinary team discussed the
appropriate treatment plan and eligibility for surgery. All
data of consecutive patients were retrospectively collected
and reviewed using electronic medical records system. This
study was approved by the Institutional Review Board of
Gangnam Severance Hospital, Yonsei University College of
Medicine (IRB No. 3-2019-0005).
Assessment parameters
Baseline demographics, including age, sex, body mass
index (BMI), the American Society of Anesthesiologists
(ASA) classification, history of previous abdominal sur-
gery, history of preoperative chemotherapy, preoperative
laboratory findings, biomarker, and characteristics of pri-
mary cancer, were collected. The PCI and CC scores were
assessed intraoperatively, according to the techniques
given by Sugarbaker et al [14]. The number and the largest
diameter of the liver metastases were measured via liver
magnetic resonance imaging. Postoperative complications
within 30 days were evaluated by the Clavien-Dindo classi-
fication [15]. Readmission was defined as admission after
discharge due to surgery-related complications. Postoper-
ative laboratory findings, except tumor markers, were
collected on the operative day, and postoperative tumor
markers were checked 1 week after the last operation.
OS was calculated from the date of surgical intervention
(in case of two-stage hepatectomy, from the date of first
surgical intervention) until the date of death or last follow-
up. However, in order to include the impact of preoperative
chemotherapy and compensate for the long period from
diagnosis to surgery, OS was recalculated from the date of
diagnosis of metastatic CRC. Progression-free survival
(PFS) was measured from the date of surgical intervention
(in case of two-stage hepatectomy, from the date of first
surgical intervention) until the date of first recurrence or
last follow-up.
Surgical technique
Intraperitoneal exploration was initially performed via mid-
line laparotomy. After assessing the extent of intraoperative
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peritoneal cancer, cytoreduction was performed according
to the Sugarbaker technique [16]. Selective peritonectomy
was performed depending on the site of peritoneal metasta-
ses, and resection of the bowel or intraperitoneal organs
was performed when the seeding tumor showed gross inva-
sion. After cytoreduction, concurrent liver surgery, includ-
ing liver resection and/or intraoperative radiofrequency
ablation, was performed. Intraoperative radiofrequency
ablation was performed to treat complex liver metastases
which are unsuitable for parenchymal resection alone.
Some of the selected patients underwent two-stage hepa-
tectomy when they had multiple liver metastases that could
not be completely resected via single-stage hepatectomy,
considering the remnant liver volume. The eligibility of
two-stage hepatectomy was determined by a multidisciplin-
ary team. Two-stage hepatectomy was complete when
patients showed resectable disease after the first-stage liver
surgery, which included portal vein ligation. HIPEC was
performed using mitomycin C (35mg/m2 at 42–43 °C)
mixed in 3 L of hypertonic solution (Dianeal®, 1.5% dextrose
peritoneal dialysis solution) using the open Coliseum tech-
nique for 90min. Mitomycin C (17.5mg/m2) was initially
administered, followed by additional administration of 8.8
mg/m2 at 30 and 60min, respectively. The resected bowel
was reconstructed after HIPEC.
Follow-up
Patients visited the outpatient clinic 1 week after being
discharged. Postoperative chemotherapy was initiated 1
week after the first visit, if a patient had no systemic
complications. Patients were followed up by using serum
tumor marker measurements, abdomino-pelvic CT, and
chest CT at 3-month intervals. If tumor recurrence was
suspected on regular follow-up imaging, positron emis-
sion tomography or liver magnetic resonance imaging
was selectively performed.
Statistical analysis
Perioperative outcomes, OS, and PFS were analyzed
using SPSS 23 (SPSS Inc., Chicago, IL). Survival time
was estimated using the Kaplan-Meier method, and re-
ported along with the confidence interval (CI).
Results
Baseline patient characteristics
A total of twenty-two patients (10 men, 12 women; me-
dian age, 56 years [range, 26–66 years]) were included in
this study. The median BMI was 23.2 kg/m2, and five pa-
tients (22.7%) had an ASA score of 3. Fourteen patients
(63.6%) had a history of previous abdominal surgery, and
12 patients (54.5%) preoperatively underwent primary
tumor resection. Sigmoid colon was the most common
site of primary CRC (n = 8, 36.4%), and moderate differ-
entiation was the most common histologic grade (n =
20, 90.9%). Twenty patients (90.9%) received preopera-
tive chemotherapy. The median value of preoperative
CEA and CA 19-9 were 11.9 ng/mL and 34.7 U/mL, re-
spectively. The median preoperative aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
were 25.5 IU/L and 21.0 IU/L, respectively. Fourteen pa-
tients (63.6%) had K-ras mutation. The median number
of liver metastases was 3 (range, 1–13), and the median
value of the largest diameter of liver metastases was 1.4
cm (range, 1–5 cm) Fifteen patients had liver metastases
in the right lobe, two patients had in the left lobe, and
five patients had in both lobes (Table 1).
Detailed surgical procedures
Detailed surgical procedures for cytoreductive surgery with
concurrent liver surgery was demonstrated in Table 2.
Various cytoreductive procedures, such as peritonectomy,
bowel resection, hysterectomy, splenectomy, and cholecyst-
ectomy, were performed. Omentectomy was the most fre-
quently performed cytoreductive procedure (n = 15, 68.2%),
and one patient underwent excision of the ureter with
ureterocystostomy due to tumor invasion of the right
ureter. Wedge resection (n = 14, 63.6%) was the most
common procedure for concurrent liver surgery. Four
patients (18.2%) underwent intraoperative radiofre-
quency ablation, and two patients underwent intraop-
erative radiofrequency alone as a replacement for
surgical resection. Six patients (27.3%) underwent
two-stage hepatectomy. Among them, three patients
underwent first-stage liver surgery, followed by CRS
and HIPEC with concurrent complete hepatectomy;
the other three patients underwent CRS and HIPEC
with concurrent liver surgery, followed by complete
hepatectomy. All of the patients with > 3 liver metas-
tases underwent two-stage hepatectomy, except for
one patient (Fig. 1); although that patient had 11 liver
metastases, they were completely resected via multiple
wedge resections during single-stage hepatectomy.
The mean duration between first-stage liver surgery
and second-stage liver surgery was 23.3 ± 17.3 days
(range, 12–58 days).
Perioperative outcomes
The median PCI was 13 (range, 0–26), and the distri-
bution of PCI was as follows: PCI < 10, n = 7 (31.8%);
PCI 10–19, n = 11 (50.0%); and PCI ≥ 20, n = 4
(18.2%). All of cytoreductive surgery was achieved CC-
0. The mean total operative time was 11.4 ± 2.6 h
(range, 7.5–16.5 h), and the mean operative time for
concurrent liver surgery was 3.0 ± 2.5 h (range, 0.5–
9.0 h). The mean estimated blood loss was 1418.6 ±
1204.1 mL (range, 250–5000 mL) and the mean intra-
operative transfusion was 475.4 ± 740.4 mL (range, 0–
3030 mL). The median postoperative CEA and CA 19-
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9 were 2.6 ng/mL and 29.4 U/mL. The median postop-
erative AST and ALT were 170.5 IU/L and 137 IU/L.
The mean lengths of intensive care unit stay and hos-
pital stay were 3.1 ± 7.9 days and 25.6 ± 16.7 days, re-
spectively. All of the patients, except for one patient
who died, received postoperative chemotherapy; and
the median interval between surgery and adjuvant
chemotherapy was 40.5 days (range, 31–63). Table 3
shows perioperative outcomes, and Fig. 2 shows a
schematic flow diagram of the treatment.
Table 2 Detailed surgical procedures for cytoreductive surgeries
with concurrent liver surgeries
Variables Total patients
(n=22)
Detailed procedures for cytoreductive surgery
Peritoneum
Diaphragmatic peritonectomy 11 (50.0)
Parietal peritonectomy 8 (36.4)
Pelvic peritonectomy 13 (59.1)
Omentectomy 15 (68.2)
Gastro-intestinal tract
Right hemicolectomy 3 (13.6)
Left hemicolectomy 2 (9.1)
Anterior resection 3 (13.6)
Low anterior resection 8 (36.4)
Ileocecectomy 2 (9.1)
Segmental resection of small bowel 8 (36.4)
Hartmann operation 1 (4.5)
Appendectomy 3 (13.6)
Gynecologic
Hysterectomy 5 (22.7)
Salpingo-oophorectomy 8 (36.4)
Others
Excision of ureter with ureterocystostomy 1 (4.5)
Cholecystectomy 8 (36.4)
Splenectomy 1 (4.5)
Detailed procedures of liver surgery
Intraoperative radiofrequency ablation 4 (18.2)
Wedge resection 14 (63.6)
Sectionectomy 1 (4.5)
Lobectomy 4 (18.2)
Extended lobectomy 1 (4.5)
Two-stage hepatectomy 6 (27.3)
1st-stage liver surgery→ CRS/HIPEC + 2nd-stage
liver surgery
3 (13.6)
CRS/HIPEC + 1st-stage liver surgery→ 2nd-stage
liver surgery
3 (13.6)
n (%); CRS cytoreductive surgery, HIPEC hyperthermic
intraperitoneal chemotherapy
Table 1 Baseline patient characteristics
Variables Total patients (n=22)
Age‡ , years 56 (26-66)
Sex*
Male : Female 10 (45.5) : 12 (54.5)
BMI‡, kg/m2 23.2 (16.2-32.2)
ASA score*
1 5 (22.7)
2 12 (54.5)
3 5 (22.7)
History of previous abdominal surgery* 14 (63.6)
Preoperative resection of primary cancer* 12 (54.5)
Primary cancer origin*
Cecal cancer 2 (9.1)
Ascending colon cancer 5 (22.7)
Descending colon cancer 2 (9.1)
Sigmoid colon cancer 8 (36.4)
Rectosigmoid junction cancer 1 (4.5)
Rectal cancer 4 (18.2)
Primary cancer histologic grade*
well-differentiated 0
moderate-differentiated 20 (90.9)
poorly-differentiated 1 (4.5)
Mucinous 0
signet ring cell 0
Unknown 1 (4.5)
Preoperative chemotherapy* 20 (90.9)
1st line 16 (72.7)
2nd line 3 (13.6)
3rd line 1 (4.5)
Preoperative laboratory findings‡
CEA , ng/mL 11.9 (0.6-408.6)
CA 19-9 , U/mL 34.7 (0.8-2606.8)
Hemoglobin , g/dL 12.7 (9.8-14.5)
Albumin , g/dL 4.2 (3.5-4.5)
Total bilirubin , mg/dL 0.6 (0.3-1.2)
AST , IU/L 25.5 (17-85)
ALT , IU/L 21 (9-56)
Biomarker*
K-ras mutation 14 (63.6)
K-ras wild type 8 (36.4)
Number of liver metastases‡ 3 (1-13)
The largest diameter of liver metastases‡, cm 1.4 (1-5)
Location of liver metastases*
Right lobe 15 (68.2)
Left lobe 2 (9.1)
Both lobes 5 (22.7)
*, n (%); ‡, median (range); BMI body mass index, ASA American Society of
Anesthesiologists, AST aspartate aminotransferase, ALT
alanine aminotransferase
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Postoperative complications
Minor postoperative complications (grade I–II: includ-
ing neutropenia, anemia, fever, diarrhea, and vomiting)
were observed in 10 patients (45.5%). Major postopera-
tive complications (grade III–V: including luminal
bleeding, bile leakage, anastomotic leakage, and septic
shock), were observed in five patients (22.7%). Three
patients (13.6%) underwent reoperation due to surgical
complications of bile leakage in one patient and anasto-
motic leakage in two patients. Of the three patients
who underwent reoperation, one patient (4.5%) died 32
days after surgery, despite reoperation for panperitoni-
tis due to anastomotic leakage. The rate of readmission
due to postoperative complications was 9.1%, with
intestinal obstruction and anastomotic leakage in one
patient each (Table 4).
Survival outcomes
The median follow-up period was 15.0months. The me-
dian OS and median PFS since surgical intervention were
16.7months (95% CI, 16.0–17.4months) and 7.1months
(95% CI, 3.2–11.0months), respectively. The median OS
since diagnosis was 27.4months (95% CI, 21.7–33.1
months) during a median follow-up of 19.7months. The
1-year OS was 100%, 2-year OS was 55.0%, 1-year PFS
was 24.2%, and 2-year PFS was 12.1% (Fig. 3). The liver
was the most frequent site of initially detected recurrence
(n = 10, 45.5%), followed by the lungs (n = 6, 27.3%) and
peritoneum (n = 4, 18.2%) (Fig. 4). Four patients did not
experience recurrence during the follow-up period.
Discussion
Surgical treatment for patients who have peritoneal metas-
tasis combined with the presence of parenchymal liver me-
tastasis has not been established. Since Elias et al. published
the first report about combined resection with intraperito-
neal chemotherapy for patients with peritoneal and liver
metastases, several surgeons have tried to attempt this
challenging surgical treatment [17]. A recently published
systematic review showed that combined curative resection
with intraperitoneal chemotherapy for peritoneal and liver
metastatic CRC resulted in a possible survival benefit in
selected patients [18]. However, there have been only a few
studies regarding this treatment, therefore the feasibility
and the efficacy is still controversial.
Our primary aim was to evaluate the clinical outcomes of
combined curative resection for synchronous peritoneal
and liver metastases. With comparison of other published
studies, our study showed comparable perioperative out-
comes. In our study, minor complication rate was 45.5% (n
= 10), major complication rate was 22.7% (n = 5), and mor-
tality rate was 4.5% (n = 1). Bile leakage occurred in only
two patients (9.1%) who were treated with endoscopic bil-
iary drainage and reoperation, respectively. These results
were comparable to those in previously published studies
that had major complication rates of 23.8–51.4% and mor-
tality rates of 0–8.1% [3, 19–24].As CRS with HIPEC has
an overall morbidity rate of 23–45% and mortality rate of
0–12% in CRC patients with peritoneal metastasis only, the
addition of concurrent liver resection does not seem to re-
duce safety [25]. Berger et al. suggested that perioperative
complication rate, length of hospital stay, and intraoperative
Fig. 1 Scatter plot showing the relation between peritoneal cancer index and number of liver metastasis. PCI peritoneal cancer index
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blood transfusion were related to more extensive cytore-
duction, rather than liver surgery itself [26]. In our study,
only one patient died of intestinal anastomotic leakage; she
had three anastomoses, which was relatively higher com-
pared to other patients, without stoma diversion. A protect-
ive stoma is recommended for extensive cytoreduction
including ≥ 2 anastomoses to reduce the anastomotic leak
rate [27].
Our study showed that the median OS since surgery was
16.7months, and that since diagnosis was 27.4months.
Downs-Canner et al. reported a median OS of 13.0months
since surgery in patients who were treated with combined
resection for colorectal peritoneal and liver metastases,
while the median OS was 32.5months since diagnosis;
these findings were comparable to our results [3]. Lorimier
et al. also calculated OS from diagnosis, and reported a me-
dian OS of 36.1months; however, only 63% of patients (n =
14) were treated with preoperative chemotherapy [24].
Maggiori et al. reported a median OS of 32.0months, al-
though they measured survival since surgery [19]. They
excluded patients with disease progression within 2–3
months after receiving preoperative chemotherapy; we also
included such patients. Therefore, in our study, four pa-
tients received more than first-line preoperative chemother-
apy, and the average interval between diagnosis and surgery
was 6.5months. Maggiori et al. suggested that better sur-
vival prognosis could be achieved when patients had PCI <
12, and the number of liver metastases was < 3 [19]. The
median OS was 40months for patients with PCI < 12 and
< 3 liver metastases, while it was 27months for patients
with PCI ≥ 12 and ≥ 3 liver metastases [19]. In our study,
only two patients met these criteria for better survival prog-
nosis, and both of them were alive for 30.2months and
20.2months until the date of the last follow-up. Carvalho
et al. showed relatively better survival outcomes, with a me-
dian OS of 44months and median PFS of 10months. These
better results might be due to the fact that the patients had
relatively lower PCI (median, 5; range, 3–10.5) and fewer
liver metastases (median, 2; range, 1–6) [20]. Our results
for OS were acceptable, despite the longer period for
Table 3 Perioperative outcomes
Variables Total patients (n=22)
Peritoneal cancer index (PCI)*
<10 7 (31.8)
10-19 11 (50.0)
≥20 4 (18.2)
Mean PCI† 12.0 ± 7.9 (0-26)
Median PCI ‡‡ 13 (3-17)
Completeness of cytoreduction (CC)
CC-0 22 (100)
CC-1 0
Total operative time†, hour 11.4 ± 2.6 (7.5-16.5)
Operative time for concurrent liver surgery†, hour 3.0 ± 2.5 (0.5-9.0)
Estimated blood loss†, mL 1418.6 ± 1204.1 (250-5000)
Intraoperative transfusion†, mL 475.4 ± 740.4 (0-3030)
Postoperative laboratory findings‡
CEA , ng/mL 2.6 (0.4-32.9)
CA 19-9 , U/mL 29.4 (4.1-232)
Hemoglobin , g/dL 10.6 (7.5-13.7)
Albumin , g/dL 2.7 (1.4-3.3)
Total bilirubin , mg/dL 1.3 (0.4-2.4)
AST , IU/L 170.5 (77-498)
ALT , IU/L 137 (30-440)
Length of ICU stay‡, days 3.1 ± 7.9 (0-38)
Length of hospital stay‡, days 25.6 ± 16.7 (9-71)
Numbers to treat adjuvant chemotherapy* 21 (95.5)
Interval between surgery and adjuvant chemotherapy‡‡, days 40.5 (31-63)
*, n (%); †, mean ± standard deviation (range); ‡, median (range); ‡‡, median (quartile); AST aspartate aminotransferase; ALT alanine aminotransferase; ICU intensive
care unit
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preoperative chemotherapy including patients with disease
progression and more severe liver metastases.
In our study, the median PFS was 7.1 months, which
was comparable to that obtained in previous studies (5.1
to 10.0 months) [3, 19–24]. The most common site of
initial recurrence was the liver (n = 10, 45.5%). Recently,
Ito et al. suggested that hepatectomy for metachronous
colorectal liver metastases after complete CRS and
HIPEC for peritoneal metastases could be performed
safely and achieved better survival outcome [28].
However, in our study, since the patients had synchron-
ous peritoneal and hepatic metastases, it would be chal-
lenging to apply repeated hepatectomy for patients who
had liver recurrence after CRS and HIPEC with concur-
rent liver surgery. According to Ito et al., 75% of patients
with metastatic CRC, who underwent hepatectomy with
curative intent, experienced recurrence in the liver be-
fore they died [4]. Moreover, one-third of the patients
ultimately showed systemic dissemination with bone or
brain metastases. This implies that even if complete re-
section is successful, systemic chemotherapy is needed
for CRC patients with hepatic metastasis.
We included six patients who underwent two-stage
hepatectomy, a relatively more aggressive treatment
strategy compared to that performed in previous studies.
Since Adam et al. reported the first series on two-stage
hepatectomy in patients with initially unresectable colo-
rectal liver metastasis, several studies have suggested
that two-stage hepatectomy was safe and effective for se-
lected patients [6, 29]. According to these studies, the
morbidity and mortality rates of two-stage hepatectomy
for multiple colorectal liver metastases ranged from 26
to 59% and from 0 to 9%, respectively [30–34]. Although
only six patients in our study underwent two-stage hepa-
tectomy, it was encouraging to see that only one patient
experienced bile leakage (grade IIIa), no patient showed
liver failure, and no patient died after CRS and HIPEC
with concurrent two-stage hepatectomy. However, to
analyze the safety and effectiveness of this procedure,
much more patients are required and the patient selec-
tion should be carefully taken. Further study regarding
two-stage hepatectomy will be conducted.
This study had several limitations, including its small
patient population, retrospective nature of analysis, and
Fig. 2 Schematic flow diagram showing treatment. CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy
Table 4 Postoperative complications
Variables Total patients (n=22)
Postoperative complications*
Grade I 1 (4.5)
Grade II 9 (40.9)
Grade IIIa 2 (9.1)
bile leakage 1 (4.5)
luminal bleeding 1 (4.5)
Grade IIIb 1 (4.5)
anastomosis leakage 1 (4.5)
Grade IV 1 (4.5)
septic shock 1 (4.5)
Grade V 1 (4.5)
Reoperation, during postoperative hospital stay 3 (13.6)
Bile leakage 1 (4.5)
Anastomosis leakage 2 (9.1)
Readmission due to postoperative complication 2 (9.1)
Intestinal obstruction 1 (4.5)
Anastomosis leakage 1 (4.5)
n (%); * classified by the Clavien-Dindo classification
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short follow-up period. However, the study results showed
acceptable morbidity and mortality rates with comparable
survival outcomes, even though patient selection was rela-
tively more extensive compared to previous studies.
Therefore, after refining the patient selection criteria
through further studies, this strategy could be effective for
CRC liver and peritoneal metastases.
Conclusions
In an experienced center, concurrent liver resection with
CRS and HIPEC was feasible and safe for selected patients,
with acceptable clinical outcomes. Nevertheless, additional
long-term follow-up studies on a large population are
needed to confirm the effectiveness of the surgical treat-
ment for patients with liver and peritoneal metastatic CRC.
Fig. 3 Overall survival and progression-free survival curves (Kaplan-Meier method). a Survival rate since surgery. b Overall survival since diagnosis
of metastatic colorectal cancer. OS overall survival, PFS progression-free survival
Fig. 4 Sites of recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with concurrent liver surgery
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